Pancreatic Cancer Research

ResearcherUniversity College DublinActive in the last 2 years

Boris Ν. Kholodenko

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9483-4975; OpenAlex author ID A5003776093. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2024: 1 paper · 2025: none · 2026: 1 paper

Papers 2

  1. Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer. Co-author DOI 10.36401/jipo-25-20↗
  2. Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cells. Last author DOI 10.1016/j.celrep.2024.114710↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Derek Cridebring · 1 shared paper, 2026 · strength 0.25
  2. Muhammad Rizwan Khawaja · 1 shared paper, 2026 · strength 0.25
  3. Gayle Jameson · 1 shared paper, 2026 · strength 0.25
  4. Haiyong Han · 1 shared paper, 2026 · strength 0.25
  5. Erkut Hasan Borazanci · 1 shared paper, 2026 · strength 0.25
  6. Daniel D. Von Hoff · 1 shared paper, 2026 · strength 0.25
  7. Thomas Sevrin · 1 shared paper, 2024 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.